Global Post-Traumatic Stress Disorder Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026

  • ID: 4564279
  • Report
  • Region: Global
  • Acute Market Reports
1 of 4

FEATURED COMPANIES

  • Apotex, Inc.
  • AstraZeneca Plc
  • Bionomics Ltd.
  • GlaxoSmithKline plc
  • Novartis AG
  • Pfizer, Inc.
  • MORE
Post-Traumatic Stress Disorder Therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2018-2026, the global post-traumatic stress disorder therapeutics market is projected to reach US$ 10,679.5 Mn by 2026, expanding at a CAGR of 4.5% from 2018 to 2026.

Market Insights
Post-traumatic stress disorder (PTSD) therapeutics market projected to an extent by US$ 10,679.5 Mn by 2026 with a CAGR of 4.5% throughout the forecast period from 2018 to 2026. Antidepressants are the class of promising drugs that play a stellar role in the market. Global post-traumatic stress disorder therapeutics market from 2018 to 2026 has been prepared based on exhaustive analysis with insights from industry professionals. The detailed study incorporates the market landscape and its growth scenarios for the forecast period from 2018 to 2026. To estimate the market size, the report ruminates branded, generic and pipeline drugs.

As per the U.S. National Comorbidity Survey Replication, around 6.8% individuals experience the ill effects of PTSD. As indicated by PTSD United, Inc. around 70% of individuals in the United States has encountered a few sorts of the shocking accident in any event once in their lives. This associate to around 223.4 million individuals. The usage rate of healthcare services is highest in case of individuals suffering from PTSD. There are various symptoms that are commonly grouped into four different types: avoidance, changes in physical and emotional reactions, negative changes in thinking and mood, and intrusive memories that are identified in the individuals having post-traumatic stress disorder.

Based on the class of drug, the global post-traumatic stress disorder therapeutics market is segmented into antidepressants, anti-anxiety drugs, other drug classes (Alpha-1 & Alpha-2 Receptor Antagonists, Atypical Antipsychotics, and Anticonvulsants), and pipeline candidates. Rising prevalence of PTSD and the promising drug pipeline would additionally boost the post-traumatic stress disorder therapeutics market.

Geographically, the overall post-traumatic stress disorder therapeutics market is projected for the Middle East and Africa, Europe, North America, Latin America, and the Asia Pacific. North America currently drives the global market and projected to hold its supremacy throughout the forecast period. However, Europe will be clearly challenged by the Asia Pacific by end of the forecast period. The need for post-traumatic stress disorder therapeutics drugs has become prominent in the Asia Pacific because of rapidly increasing events such as sexual assault, combats and inter-personal violence. There are massive chances for market penetration in countries like China, and India by the market leaders who at present have a stronghold in developed countries.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Apotex, Inc.
  • AstraZeneca Plc
  • Bionomics Ltd.
  • GlaxoSmithKline plc
  • Novartis AG
  • Pfizer, Inc.
  • MORE
Chapter 1. Preface
1.1. Report Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Assumptions

Chapter 2. Executive Summary
2.1. Global Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2017 (US$ Mn)
2.2. Global Post-Traumatic Stress Disorder Therapeutics Market, by Geography, 2017 (US$ Mn)

Chapter 3. Global Post-Traumatic Stress Disorder Therapeutics Market Overview, 2016 - 2026 (US$ Mn)
3.1. Overview
3.2. Market Drivers
3.2.1. Growing Events of Violence and Wars
3.3. Challenges
3.3.1. Lack of Timely Diagnosis and Access to Care
3.3.2. Risk of Side Effects
3.4. Opportunities
3.4.1. Promising Pipeline Candidates
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Market Competition Assessment, 2017

Chapter 4. Global Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
4.1. Overview
4.2. Antidepressants
4.2.1. SSRIs
4.2.2. SNRIs
4.2.3. MAO Inhibitors
4.2.4. Tricyclic Antidepressants
4.3. Anti-anxiety Drugs
4.3.1. Beta-blockers
4.3.2. Benzodiazepines
4.4. Other Drug Classes
4.4.1. Alpha-1 & Alpha-2 Receptor Antagonists
4.4.2. Atypical Antipsychotics
4.4.3. Anticonvulsants
4.5. Pipeline Candidates (Qualitative Information)
4.5.1. SRX 246 (Phase II)
4.5.2. BNC 210 (Phase II)
4.5.3. Tonmya (Phase II)

Chapter 5. Global Post-Traumatic Stress Disorder Therapeutics Market, by Geography, 2016 – 2026 (US$ Mn)
5.1. Overview
5.2. North America
5.2.1. North America Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.2.2. North America Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016 – 2026 (US$ Mn)
5.2.3. North America Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016 – 2026 (US$ Mn)
5.2.4. North America Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016 – 2026 (US$ Mn)
5.2.5. North America Post-Traumatic Stress Disorder Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
5.2.5.1. U.S.
5.2.5.2. Canada
5.3. Europe
5.3.1. Europe Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.3.2. Europe Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016 – 2026 (US$ Mn)
5.3.3. Europe Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016 – 2026 (US$ Mn)
5.3.4. Europe Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016 – 2026 (US$ Mn)
5.3.5. Europe Post-Traumatic Stress Disorder Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
5.3.5.1. U.K.
5.3.5.2. Germany
5.3.5.3. Rest of Europe
5.4. Asia Pacific
5.4.1. Asia Pacific Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.4.2. Asia Pacific Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016 – 2026 (US$ Mn)
5.4.3. Asia Pacific Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016 – 2026 (US$ Mn)
5.4.4. Asia Pacific Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016 – 2026 (US$ Mn)
5.4.5. Asia Pacific Post-Traumatic Stress Disorder Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
5.4.5.1. Japan
5.4.5.2. China
5.4.5.3. Rest of APAC
5.5. Latin America
5.5.1. Latin America Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.5.2. Latin America Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016 – 2026 (US$ Mn)
5.5.3. Latin America Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016 – 2026 (US$ Mn)
5.5.4. Latin America Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016 – 2026 (US$ Mn)
5.5.5. Latin America Post-Traumatic Stress Disorder Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
5.5.5.1. Brazil
5.5.5.2. Mexico
5.5.5.3. Rest of Latin America
5.6. Middle East & Africa
5.6.1. Middle East & Africa (MEA) Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.6.2. Middle East & Africa (MEA) Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016 – 2026 (US$ Mn)
5.6.3. Middle East & Africa (MEA) Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016 – 2026 (US$ Mn)
5.6.4. Middle East & Africa (MEA) Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016 – 2026 (US$ Mn)
5.6.5. Middle East & Africa (MEA) Post-Traumatic Stress Disorder Therapeutics Market, by Region, 2016 – 2026 (US$ Mn)
5.6.5.1. GCC
5.6.5.2. Rest of MEA

Chapter 6. Company Profiles
6.1. Pfizer, Inc.
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. Key Developments
6.2. GlaxoSmithKline plc
6.3. Otsuka Pharmaceutical Co., Ltd
6.4. Novartis AG
6.5. AstraZeneca Plc
6.6. Azevan Pharmaceuticals, Inc.
6.7. Bionomics Ltd.
6.8. Tonix Pharmaceuticals Holding Corp.
6.9. Apotex, Inc.

List of Figures
FIG. 1 Global Post-Traumatic Stress Disorder Therapeutics Market: Research Methodology
FIG. 2 Global Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2017 (US$ Mn)
FIG. 3 Global Post-Traumatic Stress Disorder Therapeutics Market, by Geography, 2017 (US$ Mn)
FIG. 4 Annual Number of Deaths in Combatants, 1945 to 2010
FIG. 5 Attractive Investment Proposition: Global Post-Traumatic Stress Disorder Therapeutics Market, by Geography, 2017
FIG. 6 Competitive Landscape, by Key Players, 2017
FIG. 7 Global SSRIs Market for Post-Traumatic Stress Disorder, 2016-2026 (US$ Mn)
FIG. 8 Global SNRIs Market for Post-Traumatic Stress Disorder, 2016-2026 (US$ Mn)
FIG. 9 Global MAO Inhibitors Market for Post-Traumatic Stress Disorder, 2016-2026 (US$ Mn)
FIG. 10 Global Tricyclic Antidepressants Market for Post-Traumatic Stress Disorder, 2016-2026 (US$ Mn)
FIG. 11 Global Beta-Blockers Market for Post-Traumatic Stress Disorder, 2016-2026 (US$ Mn)
FIG. 12 Global Benzodiazepines Market for Post-Traumatic Stress Disorder, 2016-2026 (US$ Mn)
FIG. 13 Global Alpha-1 & Alpha-2 Receptor Antagonists Market for Post-Traumatic Stress Disorder, 2016-2026 (US$ Mn)
FIG. 14 Global Atypical Antipsychotics Market for Post-Traumatic Stress Disorder, 2016-2026 (US$ Mn)
FIG. 15 Global Anticonvulsants Market for Post-Traumatic Stress Disorder, 2016-2026 (US$ Mn)

List of Tables
TABLE 1 Global Post-Traumatic Stress Syndrome Therapeutics Market, by Drug Class, 2016–2026 (US$ Mn)
TABLE 2 Global Antidepressants Market for Post-Traumatic Stress Syndrome, 2016–2026 (US$ Mn)
TABLE 3 Global Anti-anxiety Drugs Market for Post-Traumatic Stress Syndrome, 2016–2026 (US$ Mn)
TABLE 4 Global Other Drug Classes Market for Post-Traumatic Stress Syndrome, 2016–2026 (US$ Mn)
TABLE 5 Global Post-Traumatic Stress Syndrome Therapeutics Market, by Geography, 2016–2026 (US$ Mn)
TABLE 6 North America Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016–2026 (US$ Mn)
TABLE 7 North America Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016–2026 (US$ Mn)
TABLE 8 North America Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016–2026 (US$ Mn)
TABLE 9 North America Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016–2026 (US$ Mn)
TABLE 10 North America Post-Traumatic Stress Disorder Therapeutics Market, by Country, 2016–2026 (US$ Mn)
TABLE 11 Europe Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 12 Europe Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016–2026 (US$ Mn)
TABLE 13 Europe Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016–2026 (US$ Mn)
TABLE 14 Europe Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016–2026 (US$ Mn)
TABLE 15 Europe Post-Traumatic Stress Disorder Therapeutics Market, by Country, 2016–2026 (US$ Mn)
TABLE 16 Asia Pacific Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 17 Asia Pacific Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016–2026 (US$ Mn)
TABLE 18 Asia Pacific Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016–2026 (US$ Mn)
TABLE 19 Asia Pacific Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016–2026 (US$ Mn)
TABLE 20 Asia Pacific Post-Traumatic Stress Disorder Therapeutics Market, by Country, 2016–2026 (US$ Mn)
TABLE 21 Latin America Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016–2026 (US$ Mn)
TABLE 22 Latin America Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016–2026 (US$ Mn)
TABLE 23 Latin America Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016–2026 (US$ Mn)
TABLE 24 Latin America Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016–2026 (US$ Mn)
TABLE 25 Latin America Post-Traumatic Stress Disorder Therapeutics Market, by Country, 2016–2026 (US$ Mn)
TABLE 26 Middle East & Africa Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016–2026 (US$ Mn)
TABLE 27 Middle East & Africa Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016–2026 (US$ Mn)
TABLE 28 Middle East & Africa Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016–2026 (US$ Mn)
TABLE 29 Middle East & Africa Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016–2026 (US$ Mn)
TABLE 30 Middle East & Africa Post-Traumatic Stress Disorder Therapeutics Market, by Region, 2016–2026 (US$ Mn)
TABLE 31 Pfizer, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 32 GlaxoSmithKline plc: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 33 Otsuka Pharmaceutical Co., Ltd.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 34 Novartis AG: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 35 AstraZeneca Plc: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 36 Azevan Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 37 Bionomics Ltd.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 38 Tonix Pharmaceuticals Holding Corp.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 39 Apotex Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Pfizer, Inc.
  • GlaxoSmithKline plc
  • Otsuka Pharmaceutical Co., Ltd
  • Novartis AG
  • AstraZeneca Plc
  • Azevan Pharmaceuticals, Inc.
  • Bionomics Ltd.
  • Tonix Pharmaceuticals Holding Corp.
  • Apotex, Inc.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll